Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Dikla Atias"'
Autor:
Benjamin Assouline, Rachel Kahn, Lutfi Hodali, Reba Condiotti, Yarden Engel, Ela Elyada, Tzlil Mordechai-Heyn, Jason R. Pitarresi, Dikla Atias, Eliana Steinberg, Tirza Bidany-Mizrahi, Esther Forkosh, Lior H. Katz, Ofra Benny, Talia Golan, Matan Hofree, Sheila A. Stewart, Karine A. Atlan, Gideon Zamir, Ben Z. Stanger, Michael Berger, Ittai Ben-Porath
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly charac
Externí odkaz:
https://doaj.org/article/3aed130938ea4e87851508070eec5837
Autor:
Joo Sang Lee, Avinash Das, Livnat Jerby-Arnon, Rand Arafeh, Noam Auslander, Matthew Davidson, Lynn McGarry, Daniel James, Arnaud Amzallag, Seung Gu Park, Kuoyuan Cheng, Welles Robinson, Dikla Atias, Chani Stossel, Ella Buzhor, Gidi Stein, Joshua J. Waterfall, Paul S. Meltzer, Talia Golan, Sridhar Hannenhalli, Eyal Gottlieb, Cyril H. Benes, Yardena Samuels, Emma Shanks, Eytan Ruppin
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Synthetic lethality (SL) offers a new precision oncology approach, which is based on targeting cancer-specific vulnerabilities across the whole genome, going beyond cancer drivers. The authors develop an approach termed ISLE to identify clinically re
Externí odkaz:
https://doaj.org/article/3a4240165a2541088f4b9ac5ea8738dc
Autor:
Jonathan R. Brody, Allan M. Jordan, Dominic I. James, Donald Ogilvie, Michael J. Pishvaian, Talia Golan, Kenneth P. Olive, Jordan M. Winter, Charles J. Yeo, Dikla Atias, Yulia Glick Gorman, Chani Stossel, Maria Raitses-Gurevich, Ian D. Waddell, Kate M. Smith, Cinthya Yabar Lowder, Christopher W. Schultz, Joseph Cozzitorto, Avinoam Nevler, AnnJosette Ramirez, Saswati N. Chand, Grace A. McCarthy, Lebaron C. Agostini, Aditi Jain
Supplementary Fig S7 describes western blot and RTPCR of PARG in modified shPARG cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12baac012d9c7c055a7134059d275323
https://doi.org/10.1158/0008-5472.22421175
https://doi.org/10.1158/0008-5472.22421175
Autor:
Jonathan R. Brody, Allan M. Jordan, Dominic I. James, Donald Ogilvie, Michael J. Pishvaian, Talia Golan, Kenneth P. Olive, Jordan M. Winter, Charles J. Yeo, Dikla Atias, Yulia Glick Gorman, Chani Stossel, Maria Raitses-Gurevich, Ian D. Waddell, Kate M. Smith, Cinthya Yabar Lowder, Christopher W. Schultz, Joseph Cozzitorto, Avinoam Nevler, AnnJosette Ramirez, Saswati N. Chand, Grace A. McCarthy, Lebaron C. Agostini, Aditi Jain
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2caad1a0117fff7a23cc205bcb261f20
https://doi.org/10.1158/0008-5472.c.6510855.v1
https://doi.org/10.1158/0008-5472.c.6510855.v1
Autor:
Jonathan R. Brody, Allan M. Jordan, Dominic I. James, Donald Ogilvie, Michael J. Pishvaian, Talia Golan, Kenneth P. Olive, Jordan M. Winter, Charles J. Yeo, Dikla Atias, Yulia Glick Gorman, Chani Stossel, Maria Raitses-Gurevich, Ian D. Waddell, Kate M. Smith, Cinthya Yabar Lowder, Christopher W. Schultz, Joseph Cozzitorto, Avinoam Nevler, AnnJosette Ramirez, Saswati N. Chand, Grace A. McCarthy, Lebaron C. Agostini, Aditi Jain
Supplementary Table 1 describes BRCA and KRAS status of PDX models and IC50 of PDDX-001 and olaparib in PDAC/PDX lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026a9815acebb66132a058861657f64e
https://doi.org/10.1158/0008-5472.22421172
https://doi.org/10.1158/0008-5472.22421172
Publikováno v:
Advanced Drug Delivery Reviews. 171:257-265
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease. The majority of patients diagnosed at an advanced, metastatic stage, and poor overall survival rates. The most clinically meaningful subtype obtained from PDAC genomic classification is rep
Autor:
Ariel Shimoni-Sebag, Ifat Abramovich, Bella Agranovich, Yaarit Sirovsky, Chani Stossel, Dikla Atias, Maria Raitses-Gurevich, Yulia Glick-Gorman, Ofer Margalit, David Regev, Rotem Tal, Itay Tirosh, Talia Golan, Keren Yizhak, Eyal Gottlieb, Yaacov R. Lawrence
Publikováno v:
Cancer Research. 83:2411-2411
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is remarkably resistant to standard modalities, including radiotherapy (RT). The mechanisms of radiation resistance in general, and pancreatic cancer in particular, are poorly understood. We hypothesiz
Publikováno v:
Oncotarget
Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malign
Autor:
Ann Josette Ramirez, Talia Golan, Yulia Glick Gorman, Grace A. McCarthy, Dominic I. James, Maria Raitses-Gurevich, Avinoam Nevler, Jordan M. Winter, Dikla Atias, Michael J. Pishvaian, Chani Stossel, Joseph A. Cozzitorto, Kate M. Smith, Christopher W. Schultz, Kenneth P. Olive, Lebaron C. Agostini, Donald J. Ogilvie, Cinthya Y. Lowder, Aditi Jain, Charles J. Yeo, Saswati N. Chand, Jonathan R. Brody, Allan M. Jordan, Ian D. Waddell
Publikováno v:
Cancer Research. 79:4491-4502
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have an average survival of less than 1 year, underscoring the importance of evaluating novel targets with matched targeted agents. We recently identified that poly (ADP) ribose glycohy
Autor:
Talia Golan, Chani Stossel, Maria Raitses-Gurevitch, Dikla Atias, Tamar Beller, Steven Gallinger, Raanan Berger
Publikováno v:
Cancer Research. 82:2148-2148
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease, with the majority of patients diagnosed at an advanced stage. Comprehensive genomic analysis identified the homologous recombination deficiency (HRD) subgroup which is predominantly enriche